Phase II Study of Procarbazine, CCNU, and Vincristine Combination Chemotherapy in the Treatment of Malignant Brain Tumors

Cancer. 1975 May;35(5):1398-404. doi: 10.1002/1097-0142(197505)35:5<1398::aid-cncr2820350524>3.0.co;2-c.

Abstract

Forty-eight patients with primary or metastatic malignant tumors of the central nervous system (CNS) were treated with combination chemotherapy, consisting or procarbazine (100 mg/m2 X 14 days), CCNU (75 mg/m2), and vincristine (1.4 mg/m2 X 2, 1 week apart) (PCV) every 4 weeks. Most patients had undergone initial resection of primary tumors, postoperative radiotherapy, and a post irradiation interval of 3 months or more. Other patients harbored unbiopsied, newly-discovered primary or metastatic tumors. All patients were deteriorating neurologically when treatment began. Overall response rate for PCV combination therapy was 44%, no better than results obtained with single agent procarbazine or BCNU, the most effective drugs used alone in previous brain tumor chemotherapy studies.

Publication types

  • Comparative Study
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Brain Neoplasms / drug therapy*
  • Drug Therapy, Combination
  • Evaluation Studies as Topic
  • Humans
  • Lomustine / administration & dosage
  • Lomustine / therapeutic use*
  • Neoplasm Metastasis
  • Nitrosourea Compounds / therapeutic use*
  • Procarbazine / administration & dosage
  • Procarbazine / therapeutic use*
  • Vincristine / administration & dosage
  • Vincristine / therapeutic use*

Substances

  • Nitrosourea Compounds
  • Procarbazine
  • Vincristine
  • Lomustine